NCT07002905View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Chronic Weight Management
Interventions
DRUG

ASC30 tablets or ASC30 tablets A1 or placebo

Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily

Trial Locations (6)

33172

RECRUITING

Ascletis Clinical Site, Miami

33912

RECRUITING

Ascletis Clinical Site, Fort Myers

43212

RECRUITING

Ascletis Clinical Site, Columbus

72758

RECRUITING

Ascletis Clinical Site, Rogers

77401

RECRUITING

Ascletis Clinical Site, Bellaire

78240

RECRUITING

Ascletis Clinical Site, San Antonio

All Listed Sponsors
lead

Ascletis Pharma (China) Co., Limited

INDUSTRY

NCT07002905 - A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities | Biotech Hunter | Biotech Hunter